Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board
Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
- Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
- The new additional Aviceda Scientific Advisory Board members includes:
Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics. - She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
- The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.